Posted on Nov 11, 2021, 5:16 PMUpdated Nov 11, 2021, 7:53 PM
One more weapon in the anti-Covid arsenal of the Old Continent. The European regulator has announced that it has approved for the first time the marketing in the European Union of two monoclonal antibody treatments against the coronavirus.
The European Medicines Agency (EMA) said in a statement that it had approved the use of a treatment from the Swiss pharmaceutical company Roche, Ronapreve, and a treatment from the South Korean company Celltrion, regdanvimab. EU Health Commissioner Stella Kyriakides said approval of the two drugs was a “milestone” against the disease, with the EU relying on four vaccines so far.
Up to five new treatments
“With increases in Covid-19 contamination in almost all Member States, it is reassuring to see many promising treatments in development as part of our therapeutic strategy against Covid-19”, she added in a communicated. “Today we are taking an important step towards our goal of authorizing up to five new treatments in the EU by the end of the year,” she recalled.
Antibodies are one of the building blocks of our immune system. Faced with the presence of a dangerous element, such as a virus, our body naturally produces it to identify the invader. Synthetic antibodies make it possible to select natural antibodies, to reproduce them artificially in order to then administer them as a treatment, generally by infusion.